|
|
 Previous Article | Table of Contents | Next Article 
Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma,
Hodgkin's disease, and reactive lymphoid lesions
PG Elmberger, MD Lozano, DD Weisenburger, W Sanger and WC Chan
Department of Pathology and Cytology, Karolinska Institute and Hospital,
Stockholm, Sweden.
Anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD) have some
pathologic and immunohistochemical similarities, and a histogenetic
relationship between them has been suggested by some investigators. By
cytogenetic study, the t(2;5)(p23;q35) translocation appears to be unique
for ALCL. The breakpoints of the t(2;5)(p23;q35) have recently been cloned
and are reported to involve a novel tyrosine kinase gene, anaplastic
lymphoma kinase (alk), on chromosome 2 and the nucleophosmin gene (npm) on
chromosome 5. Therefore, we studied the frequency of npm-alk translocation
in ALCL using a reverse transcriptase-polymerase chain reaction (RT-PCR)
assay. We also studied HD and a variety of reactive lymphoid lesions since
there is contradictory information in the literature on the occurrence of
the npm-alk rearrangement in HD. We detected npm-alk hybrid mRNA in 8 of 22
cases of ALCL (36%), but none of the 21 cases of HD or the 11 cases with
reactive lesions contained amplifiable template. All positive ALCL had the
T or indeterminate phenotype and occurred in young adults or children.
There was very good correlation between a cytogenetically detectable t(2;5)
and a positive signal by RT-PCR. Our results indicate a selective but
relatively infrequent association between the t(2;5) and ALCL of T or
indeterminate phenotype, not shared with HD or reactive hyperplasia.
Volume 86,
Issue 9,
pp. 3517-3521,
11/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Schumacher, D. K. Crockett, K. S.J. Elenitoba-Johnson, and M. S. Lim
Evaluation of Enrichment Techniques for Mass Spectrometry: Identification of Tyrosine Phosphoproteins in Cancer Cells
J. Mol. Diagn.,
April 1, 2007;
9(2):
169 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. N. Deininger and B. J. Druker
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Pharmacol. Rev.,
September 1, 2003;
55(3):
401 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Kutok and J. C. Aster
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2002;
20(17):
3691 - 3702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik
Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma
J. Immunol.,
January 1, 2002;
168(1):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood,
December 1, 2000;
96(12):
3681 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. M. Reuter, M. A. Morgan, and L. Bergmann
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Blood,
September 1, 2000;
96(5):
1655 - 1669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood,
May 15, 1999;
93(10):
3167 - 3215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, N. Dastugue, K. Pulford, G. Delsol, and B. Mariame
A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation
Blood,
May 1, 1999;
93(9):
3088 - 3095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cordell, K. A.F. Pulford, B. Bigerna, G. Roncador, A. Banham, E. Colombo, P.-G. Pelicci, D. Y. Mason, and B. Falini
Detection of Normal and Chimeric Nucleophosmin in Human Cells
Blood,
January 15, 1999;
93(2):
632 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al.
ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum
Am. J. Pathol.,
September 1, 1998;
153(3):
875 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beylot-Barry, A. Groppi, B. Vergier, K. Pulford, J.P. Merlio, and t. French Study Group of Cutaneous Lymphoma
Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations
Blood,
June 15, 1998;
91(12):
4668 - 4676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mathew, W. G. Sanger, D. D. Weisenburger, M. Valentine, V. Valentine, D. Pickering, C. Higgins, M. Hess, X. Cui, D. K. Srivastava, et al.
Detection of the t(2; 5)(p23; q35) and NPM-ALK Fusion in Non-Hodgkin's Lymphoma by Two-Color Fluorescence In Situ Hybridization
Blood,
March 1, 1997;
89(5):
1678 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
